Circulating miRNAs as new activators of the JAK-STAT3 pathway

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Grothey A, Lenz HJ. Explaining the unexplainable: EGFR antibodies in colorectal cancer. J Clin Oncol 2012; 30:1735 - 7; http://dx.doi.org/10.1200/JCO.2011.40.4194; PMID: 22473160
   PubMed Web of Science ®Google Scholar
• Bernards R. It’s diagnostics, stupid. Cell 2010; 141:13 - 7; http://dx.doi.org/10.1016/j.cell.2010.03.018; PMID: 20371338
   PubMed Web of Science ®Google Scholar
• de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010; 467:543 - 9; http://dx.doi.org/10.1038/nature09339; PMID: 20882008
   PubMed Web of Science ®Google Scholar
• Mittelbrunn M, Sánchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. Nat Rev Mol Cell Biol 2012; 13:328 - 35; PMID: 22510790
   PubMed Web of Science ®Google Scholar
• D’Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 2012; 26:1287 - 99; http://dx.doi.org/10.1101/gad.192351.112; PMID: 22713869
   PubMed Web of Science ®Google Scholar
• Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 2012; 22:125 - 32; http://dx.doi.org/10.1016/j.tcb.2011.12.001; PMID: 22260888
   PubMed Web of Science ®Google Scholar
• Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011; 2:180; http://dx.doi.org/10.1038/ncomms1180; PMID: 21285958
   PubMed Web of Science ®Google Scholar
• Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 2002; 9:1031 - 44; http://dx.doi.org/10.1016/S1097-2765(02)00520-8; PMID: 12049739
   PubMed Web of Science ®Google Scholar
• Vigneron A, Roninson IB, Gamelin E, Coqueret O. Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res 2005; 65:8927 - 35; http://dx.doi.org/10.1158/0008-5472.CAN-05-0461; PMID: 16204065
   PubMed Web of Science ®Google Scholar
• Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10:619 - 24; http://dx.doi.org/10.1038/ncb1725; PMID: 18425114
   PubMed Web of Science ®Google Scholar
• Li L, Zhu D, Huang L, Zhang J, Bian Z, Chen X, et al. Argonaute 2 Complexes Selectively Protect the Circulating MicroRNAs in Cell-Secreted Microvesicles. PLoS One 2012; 7:e46957; http://dx.doi.org/10.1371/journal.pone.0046957; PMID: 23077538
   PubMed Web of Science ®Google Scholar
• Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012; 14:249 - 56; http://dx.doi.org/10.1038/ncb2441; PMID: 22327366
   PubMed Web of Science ®Google Scholar
• Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012; 31:3513 - 23; http://dx.doi.org/10.1038/emboj.2012.183; PMID: 22773185
   PubMed Web of Science ®Google Scholar
• Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30:1005 - 14; http://dx.doi.org/10.1200/JCO.2010.31.8907; PMID: 22355058
   PubMed Web of Science ®Google Scholar
• Barré B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007; 13:4 - 11; http://dx.doi.org/10.1016/j.molmed.2006.11.001; PMID: 17118707
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39:493 - 506; http://dx.doi.org/10.1016/j.molcel.2010.07.023; PMID: 20797623
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139:693 - 706; http://dx.doi.org/10.1016/j.cell.2009.10.014; PMID: 19878981
   PubMed Web of Science ®Google Scholar
• Courapied S, Sellier H, de Carné Trécesson S, Vigneron A, Bernard AC, Gamelin E, et al. The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition. J Biol Chem 2010; 285:26765 - 78; http://dx.doi.org/10.1074/jbc.M109.092304; PMID: 20516069
   PubMed Web of Science ®Google Scholar
• Vigneron A, Gamelin E, Coqueret O. The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res 2008; 68:815 - 25; http://dx.doi.org/10.1158/0008-5472.CAN-07-5115; PMID: 18245483
   PubMed Web of Science ®Google Scholar